Flovent inhalers, containing the corticosteroid fluticasone, have been a cornerstone of asthma management for decades, especially in children and adults aged four and older1 . In January 2024, GlaxoSmithKline (GSK) discontinued the branded Flovent HFA and Flovent Diskus inhalers, replacing them with authorized generic versions2 . This change has raised concerns about medication access, insurance coverage, and potential impacts on asthma control3 .
Consumer Impact of the Flovent Transition
Flovent inhalers were widely prescribed to control asthma by reducing airway inflammation and preventing attacks4 . The inhalers came in two forms: a metered-dose inhaler (Flovent HFA) and a dry powder inhaler (Flovent Diskus), both containing fluticasone propionate4 . The medication is intended for regular use, typically twice daily, to maintain symptom control1 .
Switching from branded Flovent to an authorized generic should not change the medication's effectiveness since the authorized generic contains the same active ingredient and device design5 . Proper patient education on inhaler technique is essential to ensure continued asthma control during this transition6 7. However, unsupervised or non-consented switches can lead to critical errors, reduced adherence, and worsening asthma outcomes8 .
Young children, especially those under 5 years old, may face challenges using dry powder inhalers due to insufficient lung power and coordination9 . For these patients, metered-dose inhalers with spacers or nebulized corticosteroids are preferred options10 . The authorized generic inhalers are therapeutically equivalent to Flovent but may not be covered by all insurance plans, potentially causing logistical issues for patients5 .
Data from over 3 million patients showed a 17.5% increase in asthma-related hospitalizations within three months after Flovent's discontinuation, rising to 24.1% in the following three to six months3 . Intensive care unit admissions for asthma also increased significantly during this period3 . These findings highlight the importance of careful management and monitoring during the switch.
The switch to authorized generic fluticasone inhalers should not affect asthma control if patients receive proper training on inhaler use. However, lack of insurance coverage and unfamiliar devices can lead to increased hospitalizations and emergency care. 38
Insurance Coverage and Cost Considerations
One of the most significant challenges following Flovent's discontinuation is insurance coverage for the authorized generic versions5 . Many insurance companies do not list the authorized generic fluticasone as a preferred medication, leading to higher out-of-pocket costs or denial of coverage5 . This situation can create barriers to timely medication access and disrupt asthma management11 .
Insurance coverage gaps for authorized generic fluticasone inhalers can lead to increased costs and treatment delays. Patients and caregivers should proactively communicate with healthcare providers and insurers to navigate these challenges. 115
Authorized generics are identical to the branded product but often carry higher list prices, ranging from $200 to $400 per month4 . Patients may need to seek prior authorization from their insurance providers to obtain coverage, which can delay treatment11 . Some insurers have shifted their formularies to favor dry powder inhalers or combination inhalers, which may not be suitable for all patients, especially young children or those with poor inhalation technique9 .
For children under 8 years old, dry powder inhalers are often not recommended due to the need for a strong, coordinated breath and breath-holding, which many young patients cannot perform reliably10 . Nebulized corticosteroids are an alternative but require longer administration times and additional equipment, which may be inconvenient and costly9 .
“The problem is not that the medication is not effective now that it is being sold as a generic; the problem has been that some health insurance companies are not covering the cost of it in the generic form right now.”
— Edith Bracho-Sanchez, Columbia University Irving Medical Center12
Reasons for Flovent Discontinuation
The discontinuation of branded Flovent inhalers by GSK is primarily a strategic response to changes in drug pricing policies, such as the removal of the Medicaid rebate cap in the United States13 . By discontinuing the brand and producing authorized generics, manufacturers can avoid penalties associated with rapid price increases of branded drugs13 .
“It should be made clear that the medication is still safe. There’s nothing wrong with your Flovent; they’re just not going to be making it anymore.”
— Christy Sadreameli, Johns Hopkins Hospital11
| Inhaler Type | Suitable Age Group | Notes |
|---|---|---|
| Metered-Dose Inhaler (HFA) | All ages, including young children | Requires spacer; effective for infants and toddlers10 |
| Dry Powder Inhaler (DPI) | Generally 8 years and older | Requires strong, coordinated breath; not recommended for young children9 10 |
| Nebulized Corticosteroids | All ages | Longer administration time; may be less convenient; useful if inhaler technique is poor9 10 |
Formulary-driven switches are common in asthma treatment and can be safe if the alternative medication is clinically equivalent and patients receive proper training14 7. However, non-medical switches without patient consent can negatively impact satisfaction and perceived disease control, especially if the new inhaler device is less familiar or harder to use14 . Environmental concerns about inhaler propellants are also influencing medication choices, but clinical need remains the priority15 .
Fluticasone propionate, the active ingredient in Flovent, has been favored for its efficacy, safety profile, and ease of administration in children and adults10 . The authorized generic version contains the same medication and device but may be more expensive and less likely to be covered by insurance11 .
Managing Your Asthma Medication Switch
Successfully navigating the transition from Flovent to an authorized generic or alternative inhaler requires careful planning and communication with healthcare providers. Asthma management should be individualized, considering patient ability, preference, and inhaler technique16 . Regular review of inhaler use and adherence is especially important during device transitions16 .
Proper education on inhaler technique and adherence is crucial during any medication switch to maintain asthma control and avoid exacerbations. 78
Patients may need to explore alternative inhaled corticosteroids such as beclomethasone (Qvar RediHaler), budesonide (Pulmicort Flexhaler), ciclesonide (Alvesco), or mometasone (Asmanex Twisthaler, Asmanex HFA) 4. Combination inhalers that include a long-acting bronchodilator like formoterol may also be beneficial for some patients4 .
For young children or patients who cannot use dry powder inhalers effectively, metered-dose inhalers with spacers or nebulized corticosteroids remain the preferred options10 . Patients should be vigilant for any worsening symptoms or increased asthma attacks after switching and contact their healthcare provider promptly4 .
- Fill your current Flovent prescription while supplies last to avoid gaps in treatment1 .
- Discuss with your doctor and pharmacist about the best inhaler options based on your age and ability10 .
- Check with your insurance company about coverage and whether prior authorization is needed11 .
- Learn and practice proper inhaler technique with your healthcare provider to ensure effective medication delivery16 .
- Monitor your asthma symptoms closely after switching and report any changes immediately4 .
